Janus Henderson Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-133,352
| Closed | -$17.6M | – | 2538 |
|
|
2025
Q1 | $17.6M | Buy |
133,352
+90,623
| +212% | +$11.3M | 0.01% | 597 |
|
|
2024
Q4 | $3.57M | Hold |
42,729
| – | – | ﹤0.01% | 1040 |
|
|
2024
Q3 | $3.13M | Buy |
42,729
+2,568
| +6% | +$193K | ﹤0.01% | 1089 |
|
|
2024
Q2 | $2.75M | Sell |
40,161
-361,196
| -90% | -$25.1M | ﹤0.01% | 1108 |
|
|
2024
Q1 | $27.8M | Sell |
401,357
-87,780
| -18% | -$6.03M | 0.02% | 506 |
|
|
2023
Q4 | $35M | Buy |
489,137
+8,864
| +2% | +$510K | 0.02% | 444 |
|
|
2023
Q3 | $25M | Sell |
480,273
-130,642
| -21% | -$7.61M | 0.02% | 493 |
|
|
2023
Q2 | $38.7M | Sell |
610,915
-163,625
| -21% | -$10.2M | 0.02% | 441 |
|
|
2023
Q1 | $41.9M | Buy |
774,540
+487,851
| +170% | +$23.6M | 0.03% | 416 |
|
|
2022
Q4 | $15.2M | Buy |
286,689
+59,948
| +26% | +$3M | 0.01% | 621 |
|
|
2022
Q3 | $10.5M | Buy |
226,741
+38,690
| +21% | +$2.02M | 0.01% | 663 |
|
|
2022
Q2 | $10.7M | Buy |
188,051
+61,050
| +48% | +$3.46M | 0.01% | 672 |
|
|
2022
Q1 | $7.77M | Sell |
127,001
-20,865
| -14% | -$1.08M | ﹤0.01% | 928 |
|
|
2021
Q4 | $7.73M | Buy |
147,866
+1,701
| +1% | +$71.5K | ﹤0.01% | 958 |
|
|
2021
Q3 | $5.45M | Buy |
146,165
+14,080
| +11% | +$489K | ﹤0.01% | 1036 |
|
|
2021
Q2 | $5.39M | Buy |
132,085
+14,862
| +13% | +$549K | ﹤0.01% | 1046 |
|
|
2021
Q1 | $3.98M | Buy |
117,223
+70,440
| +151% | +$2.44M | ﹤0.01% | 1048 |
|
|
2020
Q4 | $1.49M | Buy |
+46,783
| New | +$1.23M | ﹤0.01% | 1166 |
|
|
2017
Q4 | – | Sell |
-35,000
| Closed | -$552K | – | 1349 |
|
|
2017
Q3 | $552K | Hold |
35,000
| – | – | ﹤0.01% | 1230 |
|
|
2017
Q2 | $435K | Buy |
+35,000
| New | +$406K | ﹤0.01% | 1245 |
|
Other funds holding ITCI
Janus Henderson Group's ITCI Position: Q2 2025 in Review
Janus Henderson Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 133,352 shares — an estimated $17.6M sold.
Janus Henderson Group first reported a position in ITCI in Q2 2017 and held it in 20 quarters. The position peaked at $41.9M in Q1 2023. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Janus Henderson Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Janus Henderson Group sold 133,352 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $17.6M.
- Janus Henderson Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2017 and held it in 20 quarters.
- Janus Henderson Group's Intra-Cellular Therapies Inc. position peaked at $41.9M in Q1 2023.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Janus Henderson Group's 13F filing for Q2 2025, filed 14 Aug 2025.